NEO Neogenomics margins

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 40

Gross margin

44.8%

Operating margin

-6.3%

EBITDA margin

Net margin

-4.1%

Neogenomics shows its operating margin is negative at -6.3%, and its net margin is negative at -4.1%, with a gross margin of 44.8%, an operating margin of -6.3%, an EBITDA margin of 5%, and a net margin of -4.1%. Net margin had the largest improvement, gaining by 11.9 percentage points, while the other available margins also increased.

NEO margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Neogenomics recorded average margins of 43.33% gross, -14.23% operating, -0.41% EBITDA, and -12.24% net. The current gross, operating, EBITDA, and net margins are all above their three-year averages.

NEO margin expansion

Year-over-year margin changes in percentage points

Year over year, gross, operating, EBITDA, and net margins all increased, with net margin showing the largest gain at 11.9 percentage points.

Gross margin expansion

1.3pp

Operating margin expansion

10.7pp

EBITDA margin expansion

9.6pp

Net margin expansion

11.9pp

NEO Gross margin

Over the last 3 years, Neogenomics's gross margin averaged 43.33%. The current gross margin of 44.8% is 1.5 percentage points above its three-year average. During this period, gross margin reached a high of 44.8% in Sep 2026 and a low of 41.3% in Dec 2023.

NEO Operating margin

Over the last 3 years, the average operating margin for Neogenomics was -14.23%. At present, Neogenomics's current operating margin is -6.3%, which is 7.9 percentage points above its three-year average. Neogenomics's operating margin ranged from a low of -18.2% in Dec 2023 to a high of -6.3% in Sep 2026.

NEO EBITDA margin

Neogenomics recorded an average EBITDA margin of -0.41% across the last 3 years. Neogenomics currently reports an EBITDA margin of 5%, 5.4 percentage points above its three-year average. Over the last 3 years, Neogenomics's EBITDA margin peaked at 5% in Sep 2026 and reached a low of -4.6% in Sep 2025.

NEO Net margin

Across the last 3 years, Neogenomics's net margin averaged -12.24%. Against its three-year average, Neogenomics's net margin is currently -4.1%, 8.1 percentage points above its three-year average. Net margin was highest at -4.1% in Sep 2026 and lowest at -16% in Sep 2025.

NEO margin group comparison

Margins compared with peer-group, industry and sector averages

Neogenomics's gross margin of 44.8% is below the Healthcare sector and the industry average. Compared to its Healthcare sector average of 68.3%, Neogenomics's gross margin is 34% lower.

NEO margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Neogenomics's gross margin?

As of Sep 30, 2026, NEO has a gross margin of 44.8%.

What is Neogenomics's operating margin?

For the period ending Sep 30, 2026, NEO recorded an operating margin of -6.3%.

What is Neogenomics's EBITDA margin?

As of Sep 30, 2026, NEO has an EBITDA margin of 5%.

What is Neogenomics's net margin?

The current net margin for NEO is -4.1% as of Sep 30, 2026.

What are the average margins of NEO?

Across the last 3 years, NEO averaged 43.3% gross, -14.2% operating, -0.4% EBITDA, and -12.2% net.

What are the highest historical margins of NEO?

Over this 5-year history, NEO peaked at 44.8% gross in Sep 2026, -6.3% operating in Sep 2026, 11.4% EBITDA in Dec 2021, and -1.7% net in Dec 2021.

What are the lowest historical margins of NEO?

Over this 5-year history, Neogenomics's margins fell as low as 35.5% gross in Sep 2022, -35.4% operating in Jun 2022, -18.7% EBITDA in Sep 2022, and -32.9% net in Sep 2022.